{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/raynauds-phenomenon/","result":{"data":{"firstChapter":{"id":"0209e319-b6f4-5f73-ae5c-6afd753453ea","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 3af957ff-21ab-433a-9c61-4dca067ce55f --><h1>Raynaud's phenomenon: Summary</h1><!-- end field 3af957ff-21ab-433a-9c61-4dca067ce55f -->","htmlStringContent":"<!-- begin item 5091bb3a-4b08-459a-bfea-2866e80f32cc --><!-- begin field 6f15075c-b58c-46a6-a199-6ef4d960cba5 --><ul><li>Raynaud's phenomenon is episodic vasospasm of the arteries or arterioles in the extremities (usually the digits) which leads to colour change including pallor, followed by cyanosis and/or rubor.</li><li>Raynaud’s phenomenon can be classified as:<ul><li>Primary Raynaud's phenomenon (80-90% of cases) which occurs without an associated underlying condition.</li><li>Secondary Raynaud's phenomenon (10–20% of cases) which occurs in association with an underlying condition (often a connective tissue disorder such as scleroderma or systemic lupus erythematosus).</li></ul></li><li>Raynaud's phenomenon typically presents with episodes of clearly demarcated pallor of the digit(s), followed by at least one other colour change (cyanosis and/or erythema).<ul><li>Symptoms are usually precipitated by cold (or, less often, by emotion).</li><li>The characteristic tri-phasic colour change may not always be present but blanching must occur for a diagnosis to be made.</li></ul></li><li>Onset of primary Raynaud's phenomenon is usually in the second or third decade, but it can present at any age.<ul><li>Raynaud's phenomenon is more common in women than men.</li></ul></li><li>Secondary Raynaud’s should be suspected if any of the following are present:<ul><li>Digital ulcers, gangrene, or ischaemia of one or more digits.</li><li>Onset over the age of 30 years.</li><li>Episodes that are intense, painful, or asymmetrical.</li><li>History of, or clinical features suggestive of, a connective tissue disorder (such as sclerodactyly or pitting scars on the fingertips) or other causes of digital vasospasm.</li><li>Positive anti-nuclear antibody tests.</li><li>Abnormal nail-fold capillaries.</li></ul></li><li>Primary Raynaud’s phenomenon should be suspected if episodes are completely reversible and there are no features of secondary Raynaud’s phenomenon.<ul><li>Primary Raynaud’s phenomenon is uncommon in children under the age of 12 years — an underlying cause should be suspected.</li></ul></li><li>Immediate admission should be arranged if there is severe ischaemia of one or more digits.</li><li>Referral is recommended for:<ul><li>All children aged 12 years or less with features of Raynaud's phenomenon.</li><li>All people with suspected secondary Raynaud's phenomenon.</li></ul></li><li>Lifestyle measures that may help prevent an attack include:<ul><li>Keeping the whole body warm and not allowing the hands and feet to get cold — wear gloves and warm footwear in cold environments and consider using hand and foot warming devices.</li><li>Avoiding sudden temperature changes.</li><li>Avoiding or stopping smoking.</li><li>Minimizing stress if this is a trigger.</li><li>Exercising regularly.</li></ul></li><li>If lifestyle measures fail and symptoms are having a significant negative impact, a trial of nifedipine as prophylaxis can be considered.<ul><li>For young people aged 13 to 17 years, specialist advice is required before treating.</li><li>For adults 18 years or older, consider prescribing either an immediate- or modified-release (off-label) preparation — up to three-quarters of people may experience adverse effects, such as oedema, palpitations, headache, flushing, or dizziness.</li><li>If symptoms are poorly controlled despite appropriate treatment, referral should be arranged.</li></ul></li></ul><!-- end field 6f15075c-b58c-46a6-a199-6ef4d960cba5 --><!-- end item 5091bb3a-4b08-459a-bfea-2866e80f32cc -->","topic":{"id":"255ee7a1-48e0-54c2-a732-4e03fba17a60","topicId":"e0f3a627-69e7-4258-bfd3-06ad68e3ba94","topicName":"Raynaud's phenomenon","slug":"raynauds-phenomenon","aliases":[],"chapters":[{"id":"0209e319-b6f4-5f73-ae5c-6afd753453ea","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9bb70ded-aa7a-5909-9d84-111f559bccc8","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"47c14b87-688e-5e8e-af1c-e6614c461561","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"ad9e53ac-9556-5bdd-aa04-09e22fccd689","slug":"changes","fullItemName":"Changes"},{"id":"aa95064f-a6c4-5317-a6ec-33fca3665fa5","slug":"update","fullItemName":"Update"}]},{"id":"0346daa7-fb38-5512-b2c8-7f0d5d4b7c91","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"074b9165-8cc3-56b5-a9fa-483516a026aa","slug":"goals","fullItemName":"Goals"},{"id":"dadcf48d-9a98-54cf-baab-c0b65179b8f1","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d272b294-ed60-5488-8640-d756cbe670a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9dcdeaed-4201-583c-a5a9-5dcb4ead9acb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c107602-0bb8-52d9-b277-5639494a105e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72ac11d0-1027-5c50-ae82-9ae1e1bf92b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0559a1bc-62df-54ef-846b-db71b06fbe87","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2ec7ca08-f644-50e8-b54e-c6378c7053b0","slug":"definition","fullItemName":"Definition"},{"id":"951db58c-3bcb-56ef-be5f-1e0fd9fdbd81","slug":"causes-of-or-diseases-associated-with-raynauds-phenomenon","fullItemName":"Causes of, or diseases associated with Raynaud's phenomenon:"},{"id":"b9b9e063-b592-5419-8f15-8f350c8de255","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"16789ea7-d3e6-5c24-a51f-e9f57845b88b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b914d639-5ff2-526f-86e9-1280331ece9b","slug":"complications","fullItemName":"Complications"}]},{"id":"1478d9b3-2ba3-5103-9fab-2a67d58f88f4","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"509776f6-588e-5896-9432-bf45ef2f63e1","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a10980a-a167-52bd-9991-be6f6cd68c50","slug":"assessment","fullItemName":"Assessment"},{"id":"ab1aab22-cf2f-584c-b073-a5bba7ae4c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"143745f3-74bd-57da-b042-3dd311837d98","slug":"management","fullItemName":"Management","subChapters":[{"id":"f6006983-20db-5702-8a8c-9763d45ab3cf","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ede08fed-d06c-5c6c-9c34-9ada648e6c09","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"1c7cb268-2a82-5737-b0ee-332487a61ea1","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"f6403106-c5ec-5705-bdcf-a225c5de60f9","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"8a93fc9c-f20c-58a4-a5db-33420cd3b27a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"e2a1391d-6c3d-5d36-b072-abc59f16980c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"bfa3b4f4-feec-59d7-9574-f36fc1bcf5cd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"18ed7dfb-e0e7-5be9-9a57-0ab24f1666c5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2bf5741c-d447-5f96-8155-861976265e79","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"52d565ac-2dac-556a-9bc8-c5c8946df2ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1b7e64ea-3359-5d63-93ff-6b661619a25e","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"255ee7a1-48e0-54c2-a732-4e03fba17a60","topicId":"e0f3a627-69e7-4258-bfd3-06ad68e3ba94","topicName":"Raynaud's phenomenon","slug":"raynauds-phenomenon","aliases":[],"topicSummary":"Raynaud's phenomenon is episodic vasospasm of the arteries in the extremities.","lastRevised":"Last revised in February 2020","nextPlannedReviewBy":"2025-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2025-01","nextPlannedReviewByDisplay":"January 2025","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"}],"chapters":[{"id":"0209e319-b6f4-5f73-ae5c-6afd753453ea","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9bb70ded-aa7a-5909-9d84-111f559bccc8","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"47c14b87-688e-5e8e-af1c-e6614c461561","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"ad9e53ac-9556-5bdd-aa04-09e22fccd689","slug":"changes","fullItemName":"Changes"},{"id":"aa95064f-a6c4-5317-a6ec-33fca3665fa5","slug":"update","fullItemName":"Update"}]},{"id":"0346daa7-fb38-5512-b2c8-7f0d5d4b7c91","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"074b9165-8cc3-56b5-a9fa-483516a026aa","slug":"goals","fullItemName":"Goals"},{"id":"dadcf48d-9a98-54cf-baab-c0b65179b8f1","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d272b294-ed60-5488-8640-d756cbe670a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9dcdeaed-4201-583c-a5a9-5dcb4ead9acb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c107602-0bb8-52d9-b277-5639494a105e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72ac11d0-1027-5c50-ae82-9ae1e1bf92b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0559a1bc-62df-54ef-846b-db71b06fbe87","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2ec7ca08-f644-50e8-b54e-c6378c7053b0","slug":"definition","fullItemName":"Definition"},{"id":"951db58c-3bcb-56ef-be5f-1e0fd9fdbd81","slug":"causes-of-or-diseases-associated-with-raynauds-phenomenon","fullItemName":"Causes of, or diseases associated with Raynaud's phenomenon:"},{"id":"b9b9e063-b592-5419-8f15-8f350c8de255","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"16789ea7-d3e6-5c24-a51f-e9f57845b88b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b914d639-5ff2-526f-86e9-1280331ece9b","slug":"complications","fullItemName":"Complications"}]},{"id":"1478d9b3-2ba3-5103-9fab-2a67d58f88f4","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"509776f6-588e-5896-9432-bf45ef2f63e1","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a10980a-a167-52bd-9991-be6f6cd68c50","slug":"assessment","fullItemName":"Assessment"},{"id":"ab1aab22-cf2f-584c-b073-a5bba7ae4c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"143745f3-74bd-57da-b042-3dd311837d98","slug":"management","fullItemName":"Management","subChapters":[{"id":"f6006983-20db-5702-8a8c-9763d45ab3cf","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ede08fed-d06c-5c6c-9c34-9ada648e6c09","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"1c7cb268-2a82-5737-b0ee-332487a61ea1","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"f6403106-c5ec-5705-bdcf-a225c5de60f9","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"8a93fc9c-f20c-58a4-a5db-33420cd3b27a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"e2a1391d-6c3d-5d36-b072-abc59f16980c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"bfa3b4f4-feec-59d7-9574-f36fc1bcf5cd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"18ed7dfb-e0e7-5be9-9a57-0ab24f1666c5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2bf5741c-d447-5f96-8155-861976265e79","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"52d565ac-2dac-556a-9bc8-c5c8946df2ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1b7e64ea-3359-5d63-93ff-6b661619a25e","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"255ee7a1-48e0-54c2-a732-4e03fba17a60"}},"staticQueryHashes":["3666801979"]}